This study investigates the use of a molecular imaging probe to detect the location and size of prostate cancer lesions in patients with low and intermediate risk. The probe, combined with an advanced imaging system, aims to improve the accuracy of biopsies and staging of prostate cancer. Prostate cancer is a disease where cells in the prostate gland grow uncontrollably, and this study seeks to better understand how to identify these cancerous areas accurately.

In this study, participants will undergo imaging tests using a special probe during routine procedures like biopsies or surgeries. The accuracy of this probe will be compared to standard imaging techniques, like MRI, to see if it provides better information. A detailed analysis of the removed tissue will be done to verify the probe's accuracy. This testing requires collaboration among surgeons, radiologists, and scientists.

• Who can participate: Men with low or intermediate risk prostate cancer who are scheduled for a biopsy, focal treatment, or surgery can participate. Participants must be able to remain still for about 50 minutes during an MRI scan. Those in other studies with radiation exposure or who have certain medical conditions may not qualify.
• Study details: Participants will undergo imaging tests with a molecular probe during their scheduled biopsy or surgery. This involves lying still for imaging procedures, which help compare the probe's accuracy with standard MRI scans. A placebo is not involved in this study.